Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”
Executive Summary
Lilly's conduct of Phase I clinical trials for Zyprexa prior to applying for a composition/use patent did not constitute a prior "public use" that would render the patent invalid, an Indianapolis federal judge ruled April 14
You may also be interested in...
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call
Lilly Restructuring Positions Leichleiter As Heir Apparent To CEO Taurel
Lilly's promotion of John Leichleiter to president and chief operating officer positions him as the likely successor to CEO Sidney Taurel